Last reviewed · How we verify
Mometasone furoate 220
Mometasone furoate 220 is a Small molecule drug developed by California Allergy and Asthma Medical Group, Inc.. It is currently FDA-approved.
Mometasone furoate 220, marketed by California Allergy and Asthma Medical Group, Inc., is an established treatment in the allergy and asthma market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Mometasone furoate 220 |
|---|---|
| Sponsor | California Allergy and Asthma Medical Group, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386) (PHASE2)
- Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2 (PHASE2)
- Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED) (PHASE4)
- Onset and Duration of Mometasone by Oscillometry and Spirometry (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mometasone furoate 220 CI brief — competitive landscape report
- Mometasone furoate 220 updates RSS · CI watch RSS
- California Allergy and Asthma Medical Group, Inc. portfolio CI